Aims The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0–100%), fibrinolysis (18.8%; 0–100%), and no reperfusion therapy (9.0%; 0–75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5–5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8–97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1–70.1%) for timely reperfusion. Conclusions The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.
Цель. Сопоставить эффекты 3-месячной терапии фиксированной комбинацией ингибитора ангиотензинпревращающего фермента (периндоприла) и тиазидоподобного диуретика (индапамида) в генетически гетерогенных подгруппах больных артериальной гипертонией (АГ) для оценки возможности выбора режима антигипертензивной терапии, основанной на результатах генетического тестирования. Материал и методы. Для реализации поставленной цели обследован 41 больной АГ 1-2 степени с недостаточной эффективностью предшествующей антигипертензивной терапии и 20 здоровых лиц, для сравнения частоты встречаемости полиморфизма генов в Ростовской области. Больным АГ был выполнен стандартный объем обследования, а также молекулярно-генетическое исследование по определению наиболее клинически значимых полиморфных генов, участвующих в патогенезе АГ. Результаты. Установлена связь между клиническими и морфофункциональными особенностями АГ у обследованного контингента больных с полиморфизмом генов AGT, AGTR2, CYP11B2, GNB3, NOS3: -786, из которых 3 полиморфных гена (AGT, AGTR2, CYP11B2) кодируют активность ангиотензинпревращающего фермента. Проведена оценка терапевтической эффективности назначения в качестве стартовой антигипертензивной терапии препарата из класса ингибиторов ренин-ангиотензин-альдостероновой системы в классической комбинации с тиазидоподобным диуретиком. Сопоставление эффектов использованной фиксированной комбинации периндоприла (10,0) и индапамида (2,5) (Нолипрел А Би-форте) в генетически гетерогенных подгруппах больных АГ позволило установить более выраженные антигипертензивные и органопротективные эффекты у лиц, имеющих в генотипе "мутантную" аллель 704C полиморфизма T704C AGT. Продемонстрировано достоверно более значимое снижение артериального давления по стандартным показателям суточного мониторирования артериального давления (p<0,05). Достоверно более значимое уменьшение индекса массы миокарда левого желудочка (p=0,0001), а также достоверное увеличение показателя трансмитрального кровотока (VЕ/VА МК), p=0,0024. Положительное влияние терапии на все показатели жесткости артериальной стенки: уменьшение параметров скорости пульсовой волны (p=0,0035), сосудистого возраста (VA) (p=0,00002) и индекса отражения (Ri) (p=0,000001), по сравнению с пациентами с отсутствием носительства "мутантной" аллели 704С гена AGT. Заключение. Полученные результаты свидетельствует о перспективности использования генетических подходов для выработки персонифицированной тактики медикаментозного лечения больных АГ с целью повышения ее эффективности.Ключевые слова: артериальная гипертензия, полиморфизм генов, ренинангиотензин-альдостероновая система, ингибитор ангиотензинпревращающего фермента. Отношения и деятельность: нет. 1 ФГБОУ ВО Ростовский государственный медицинский университет Минздрава России, Ростов-на-Дону; 2 ГБУ РО Областная клиническая больница № 2 Минздрава России, Ростов-на-Дону, Россия.
Objective: to assess the prospects of using genetic testing for early detection of patients with arterial hypertension (AH) with a high risk of developing coronary heart disease (IHD).Material and methods: we examined 100 patients with hypertension, who were divided into 2 groups: patients with hypertension without ischemic heart disease (62%, 62 people) and patients with hypertension with ischemic heart disease (38%, 38 people). All patients underwent a standard volume of diagnostic procedures, as well as molecular genetic research. Results: the specificity of the carriage of gene polymorphism was revealed, depending on the presence of isolated AH or AH in combination with IHD in patients. Patients with AH and IHD are characterized by the presence of the CC genotype and the C allele of the ΝΟS3 gene (p = 0,040 and p = 0,035), while the TT genotype of the T‑786C polymorphic marker of the NOS3 gene is characteristic of patients with isolated AH. Conclusion: the study of the genetic aspects of comorbidity is theoretically important for understanding the mechanisms of its formation. From a practical point of view, the opportunity to use modern genetic approaches for early screening of hypertensive patients with a high risk of developing cardiac comorbid pathology is valuable.
Aim. To study the effect of gender, age, duration of disease and different forms of ischemic heart disease on the stiffness of the vascular wall in patients with arterial hypertension by determining the propagation velocity of the pulse wave. Materials and methods. In order to study the propagation velocity of the pulse wave it was examined 369 patients with the method of volumetric sphygmography. In all patients was diagnosed arterial hypertension I-III stage, 1-3 degree, besides 47 patients were diagnosed with stable angina I-III functional class, 50 patients had a history of prior myocardial infarction. The investigation was held with the help of hardware complex "Poli-Spektr" made by Neirosoft firm (city Ivanovo) by the classical method of determining the propagation velocity of the pulse wave using synchronous registration sphygmograms of the carotid, radial and femoral arteries. Results. Patients with arterial hypertension had statistically higher velocity of pulse wave propagation for elastic-type vessels in comparison with healthy volunteers (9.48±0.18 и 7.28±0.64 cm/sec; р
Recent data indicate that it is important to develop the problem of genetic polymorphism in patients with arterial hypertension (AH) for the long-term possibility of using it as a justification for choosing the optimal treatment strategy. Currently, despite the availability of effective antihypertensive agents, the percentage of patients who have reached the target blood pressure level remains still not enough. A rational basis for choosing a particular class of drugs and / or their combinations in a concrete patient with AH can be the detection of genetic markers that determine the degree of sensitivity to therapy, since the relationship of its effectiveness with the genetic features is not in doubt today. Material and methods The work is based on the results of a clinical, instrumental, laboratory and genetic examination of 41 patients with AH with insufficient effectiveness of previous antihypertensive therapy. The median age and duration of the disease were 54 (32; 70) years and 7 (1; 20) years, respectively. Taking into account the identified gene polymorphism, a fixed combination of an ACE inhibitor (perindopril 10 mg) and a thiazide-like diuretic (indapamide 2.5 mg) was assigned. The comparative dynamics of blood pressure daily monitoring, left ventricle echocardiographic parameters, as well as indicators of vascular wall stiffness were analyzed before therapy and 3 months later. Results The study established a relationship between the clinical and morpho-functional features of AH in the examined patients with polymorphism of the AGT, AGTR2, CYP11B2, GNB3, NOS3 genes:-786 of their heterozygotes and “mutant” homozygotes, of which 3 polymorphic genes (AGT, AGTR2, CYP11B2) encode the activity of ACE. The obtained results allowed to establish that positive dynamics of the studied indicators was revealed in all patients. Though patients, carriers of the mutant allele C of polymorphic marker T704C AGT gene, had statistically significant more expressed benefit changes in blood pressure daily profile, echocardiographic parameters (such as left ventricular mass index, indicators of left ventricular diastolic function) and all parameters of arterial wall stiffness compared with patients who do not carry the “mutant” allele. Conclusion Thus, the selected treatment regimen demonstrated maximum antihypertensive, cardio - and vasoprotective effectiveness in the group of AH patients with the presence of the allele 704C of the polymorphic marker T704C of the AGT gene, which indicates the perspectivity of using genetic approaches to develop personalized tactics of AH patients drug treatment. Funding Acknowledgement Type of funding source: None
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.